CBD Oil for Sleep and Systemic Sclerosis (Scleroderma): Nocturnal GERD and Esophageal Dysmotility in Recumbency, Raynaud's Cold-Triggered Digit Vasospasm, Fibrotic Chest Wall Respiratory Anxiety, and the TGF-β/CB2/TRPV1 Sleep Protocol
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Systemic sclerosis (SSc), commonly called scleroderma, is a rare chronic autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and progressive fibrosis affecting the skin and multiple internal organs. SSc affects approximately ninety thousand to one hundred thousand Americans, with a female predominance of approximately four to one, and peak onset in the fourth to sixth decades. The disease is classified into two principal subtypes defined by the extent of skin fibrosis: limited cutaneous SSc (lcSSc, formerly CREST syndrome — Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias), in which skin thickening is confined to the fingers, hands, forearms, face, and neck distal to the elbows and knees, and comprises approximately sixty to seventy percent of SSc cases; and diffuse cutaneous SSc (dcSSc), in which fibrosis extends to the trunk and proximal extremities, involves internal organs more rapidly and severely, and comprises approximately thirty to forty percent. The pathophysiology of SSc involves three interconnected processes: (1) immune activation — T-cell, B-cell, and innate immune dysregulation producing autoantibodies (anti-topoisomerase I/Scl-70 in dcSSc associated with interstitial lung disease; anti-centromere/ACA in lcSSc associated with pulmonary arterial hypertension; anti-RNA polymerase III associated with rapid-onset dcSSc and renal crisis); (2) vasculopathy — structural and functional injury to small blood vessels, producing the Raynaud's phenomenon present in nearly one hundred percent of SSc patients, digital ulcers, and eventually pulmonary arterial hypertension (PAH) in fifteen to thirty percent; and (3) fibrosis — TGF-β/Smad pathway-driven activation of fibroblasts into myofibroblasts that deposit excess collagen and extracellular matrix in the skin, lungs, heart, kidneys, and gastrointestinal tract. The GI tract is involved in approximately ninety percent of SSc patients — the most frequently involved internal organ — and esophageal dysmotility (impaired lower esophageal sphincter and esophageal peristalsis from smooth muscle fibrosis and autonomic neuropathy) is present in approximately seventy-five to ninety percent. Interstitial lung disease (ILD) affects approximately forty to sixty percent of SSc patients and is the leading cause of SSc-related mortality. Pulmonary arterial hypertension (PAH) affects approximately fifteen to thirty percent of lcSSc patients. Treatment is organ-targeted: immunosuppression (mycophenolate mofetil for ILD and skin; cyclophosphamide for severe ILD; rituximab for refractory disease); vasodilators (calcium channel blockers for Raynaud's, phosphodiesterase-5 inhibitors and endothelin receptor antagonists for PAH); proton pump inhibitors and prokinetics for esophageal/GI disease; nintedanib or pirfenidone for progressive ILD.
Systemic sclerosis produces three sleep disruption mechanisms that are entirely distinct from all prior posts in this series, including PsA (P11-270), AS (P11-269), and ET (P11-268). First and most distinctive: nocturnal GERD from esophageal dysmotility — the gastroesophageal reflux disease and microaspiration that occur specifically in the recumbent position from SSc-related lower esophageal sphincter incompetence and impaired esophageal clearance (SSc esophageal dysmotility is mechanistically and anatomically different from EoE in P11-260, which is eosinophilic mucosal inflammation disrupting swallowing, not smooth-muscle fibrosis producing LES incompetence and peristaltic failure). Second: Raynaud's phenomenon nocturnal cold-triggered digital vasospasm — the cold-triggered episodic vasospasm producing blanching, cyanosis, and ischemic pain in the digits that is physiologically the opposite of the heat-triggered erythromelalgia of PsA and PV (Raynaud's = cold triggers vasoconstriction and ischemia → pallor → cyanosis → reactive hyperemia pain; erythromelalgia = heat triggers vasodilatation → burning → redness). Nocturnal Raynaud's attacks are provoked by the temperature drop when bedding is shifted, when hands emerge from covers, or when ambient room temperature drops overnight. Third: fibrotic chest wall and interstitial lung disease respiratory restriction anxiety — the combination of mechanical chest wall compliance reduction from skin fibrosis and subcutaneous tethering, ILD-related reduced vital capacity and impaired gas exchange, and the anxiety produced by awareness of reduced respiratory reserve during the pre-sleep vulnerability period when respiratory effort is most conspicuous.
CBD Oil and SSc Medications: Mycophenolate, Cyclophosphamide, Rituximab, Calcium Channel Blockers, PDE5 Inhibitors, Endothelin Receptor Antagonists, Nintedanib, Pirfenidone, and PPIs
Mycophenolate mofetil (MMF, CellCept) — first-line immunosuppressant for SSc-ILD and skin, CYP-independent metabolism, no pharmacokinetic interaction: MMF is converted to mycophenolic acid (MPA), which is metabolized primarily by glucuronidation (UGT enzymes), not CYP. No significant CYP-mediated CBD pharmacokinetic interaction expected. MPA is also an enterohepatic recirculating compound — its biliary recirculation is not CYP-dependent. Physician disclosure for completeness. This is the most commonly used immunosuppressant in SSc and the most frequently encountered in the SSc CBD consultation — clean CBD interaction profile simplifies the conversation.
Cyclophosphamide — IV or oral alkylating agent for severe SSc-ILD, CYP2B6/3A4 activation to active metabolite, theoretical CBD interaction: Cyclophosphamide is a prodrug activated by CYP2B6 (primary) and CYP3A4 to phosphoramide mustard (the active alkylating agent) and acrolein. CBD is a CYP3A4 inhibitor — theoretical concern that CBD could modestly reduce CYP3A4-mediated activation of cyclophosphamide, potentially reducing efficacy. This is a low-magnitude theoretical interaction (CYP2B6 is the primary activator and is not significantly inhibited by CBD), but given the high stakes of cyclophosphamide therapy for severe SSc-ILD, patients on cyclophosphamide should disclose CBD to their pulmonologist and rheumatologist and defer CBD use to periods between IV cyclophosphamide infusion cycles where possible. CBD is not contraindicated with cyclophosphamide but warrants physician-level discussion.
Rituximab — biologic B-cell depleting monoclonal antibody for refractory SSc, proteolytic metabolism, clean CBD interaction: Same clean CBD pharmacokinetic profile as all biologic monoclonal antibodies in prior posts. Physician disclosure for completeness.
Calcium channel blockers (nifedipine, amlodipine, diltiazem) for Raynaud's — CYP3A4 substrate for all three, moderate CBD interaction, most important first-line Raynaud's medication CBD interaction: All three calcium channel blockers commonly used for Raynaud's in SSc are CYP3A4 substrates. CBD's CYP3A4 inhibition can modestly increase plasma levels of these agents, potentially enhancing vasodilatory and hypotensive effects (flushing, headache, ankle edema, hypotension). Nifedipine and amlodipine are the most commonly used — both CYP3A4-dependent. Physician disclosure required; monitoring for enhanced side effects particularly with nifedipine (which already commonly causes flushing and headache that could be amplified).
PDE5 inhibitors (sildenafil, tadalafil) for PAH and Raynaud's — CYP3A4 substrates, moderate CBD interaction, most important SSc-PAH medication CBD interaction: Sildenafil and tadalafil are CYP3A4 substrates. CBD's CYP3A4 inhibition can increase PDE5 inhibitor plasma levels, potentially enhancing vasodilation and hypotension (particularly with sildenafil's shorter half-life vs. tadalafil's longer half-life making the interaction more clinically significant with tadalafil's cumulative exposure). For SSc-PAH patients on PDE5 inhibitors, CYP3A4 interaction is the most important CBD pharmacokinetic consideration — physician consultation required. Endothelin receptor antagonists (bosentan, macitentan, ambrisentan): bosentan is a CYP3A4 and CYP2C9 substrate (and inducer) — complex CYP profile; ambrisentan is a CYP3A4 substrate; macitentan is CYP3A4-dependent. All endothelin receptor antagonists used for SSc-PAH require physician consultation before CBD addition due to CYP3A4 interaction.
Nintedanib (Ofev) for SSc-ILD — CYP3A4 substrate, moderate CBD interaction, most important antifibrotic medication CBD interaction: Nintedanib is an oral tyrosine kinase inhibitor antifibrotic approved for SSc-ILD (also for IPF). It is a CYP3A4 substrate — CBD's CYP3A4 inhibition can modestly increase nintedanib plasma levels, potentially worsening GI adverse effects (nausea, diarrhea — already the most common nintedanib side effects). Pirfenidone is metabolized primarily by CYP1A2 with minor CYP2C9/2D6/2E1 contributions — CBD's modest CYP1A2 inhibition could marginally elevate pirfenidone levels. Both antifibritics require physician disclosure before combining with CBD. Proton pump inhibitors (omeprazole, pantoprazole, lansoprazole) for SSc-GERD: omeprazole and lansoprazole are CYP2C19 substrates with some CYP3A4; pantoprazole is primarily CYP2C19. CBD is a modest CYP2C19 inhibitor — theoretical modest PPI level increase, generally clinically well-tolerated and unlikely to require dose adjustment, but worth disclosing given the central role of PPIs in SSc GI management.
How Systemic Sclerosis Disrupts Sleep: The Three SSc-Specific Channels Unique in This Series
1. Nocturnal GERD and Esophageal Dysmotility: Recumbency-Triggered Acid Reflux and Microaspiration From SSc-Specific Lower Esophageal Sphincter Incompetence and Peristaltic Failure
SSc esophageal involvement is the most sleep-disruptive GI mechanism in this series and is mechanistically distinct from all prior GI-adjacent posts (EoE in P11-260, PBC in P11-259, IBD-associated spondylitis in AS). The SSc esophagus undergoes a two-stage fibrotic injury: first, the autonomic nervous system supplying the esophageal smooth muscle is disrupted by SSc vasculopathy (ischemic injury to the autonomic neural network in the esophageal wall), producing early-stage neurogenic dysfunction of the lower esophageal sphincter (LES) and impaired peristalsis before fibrosis is established; second, progressive TGF-β-driven fibrosis replaces the smooth muscle of the esophagus (particularly the distal two-thirds, where smooth muscle is predominant) with collagen, permanently impairing peristaltic contractile function and LES competence. The two-stage injury produces a combined aperistalsis (absent or severely reduced peristaltic contractions throughout the esophageal body) and LES hypotension (resting LES pressure reduced below ten mmHg in severe disease) that creates a structurally incompetent esophago-gastric junction. In the upright position during waking hours, gravity provides partial compensation for LES incompetence and absent peristalsis — food and refluxate tend to fall toward the stomach. In the recumbent position during sleep, this gravitational compensatory mechanism is eliminated: gastric acid and pepsin freely reflux through the incompetent LES into the aperistaltic esophagus, where there is no clearing peristalsis to move refluxate back to the stomach. The refluxate pools in the esophagus and eventually reaches the hypopharynx, where microaspiration into the airway during the reduced-reflex state of sleep produces the characteristic SSc nocturnal symptoms: acid awakening (burning chest and throat pain from esophageal acid exposure awakening the patient from sleep), coughing and choking episodes from laryngeal acid exposure and microaspiration, and regurgitation of gastric contents into the mouth during sleep. The microaspiration of acid into the airway during sleep is also a significant contributor to SSc-ILD progression (acid microaspiration is a recognized mechanism of progressive fibrosis in SSc pulmonary disease) — making the sleep GERD problem both a direct sleep disruptor and a disease-progression mechanism that makes adequate management therapeutically imperative. CBD's CB1 mechanism in the esophageal and GI smooth muscle provides a relevant biological rationale: CB1 receptors are expressed on enteric neurons throughout the GI tract, including the lower esophageal sphincter's neural supply. Endocannabinoid system modulation through FAAH inhibition increases anandamide at CB1 receptors on the LES neural plexus, reducing the excessive smooth muscle relaxation of the dysfunctional LES; CB2/NF-κB anti-inflammatory action addresses the ongoing neuroinflammation of the SSc autonomic neuropathy contributing to LES dysfunction. The ANS parasympathetic shift from CBD's adenosine/ENT1 blockade mechanism also supports the vagal tone component of esophageal motility — parasympathetic (vagal) drive increases LES tone and promotes peristalsis, and the SSc autonomic imbalance tilting toward sympathetic dominance is partially addressed by CBD's parasympathetic-promoting mechanism. CBD cannot reverse established smooth muscle fibrosis, but it addresses the neurogenic and inflammatory contributors to LES incompetence that are present alongside — and in some patients precede — the fibrotic component.
2. Raynaud's Phenomenon Nocturnal Cold-Triggered Vasospasm: The Physiological Opposite of Erythromelalgia, Producing Ischemic Digit Pain From Vasoconstriction Rather Than Vasodilation
Raynaud's phenomenon (RP) in SSc is nearly universal (occurring in approximately ninety-five to ninety-eight percent of SSc patients) and represents the most severe, structurally-based Raynaud's in clinical medicine — distinguished from primary Raynaud's (which occurs in healthy young women without underlying connective tissue disease) and from Raynaud's secondary to other autoimmune conditions by the structural SSc vasculopathy: capillary loss, intimal proliferation, and luminal narrowing of digital arteries superimposed on the functional vasospastic attacks that characterize all Raynaud's subtypes. The Raynaud's attack sequence — triphasic in classic presentation — involves: (1) pallor phase: cold or emotional trigger activates excessive sympathetic alpha-2 adrenergic vasoconstriction in the digital arteries; in SSc, structurally narrowed lumens undergo near-complete vasoocclusion at cold temperatures that would produce only modest vasoconstriction in normal vasculature; pallor from digital ischemia; (2) cyanosis phase: deoxygenation of the stagnant blood in ischemic digits produces blue-purple discoloration; (3) reactive hyperemia phase: when the vasospasm resolves (warming, rewarming, sympathetic withdrawal), reactive vasodilation of the ischemic vasculature produces red flushing, throbbing, and burning pain from the sudden reperfusion of ischemic tissue. The nocturnal Raynaud's trigger profile is distinct from daytime triggers: the primary nocturnal triggers are ambient temperature drops (the fall in room temperature in the second half of the night as building heating systems cycle down or as outdoor temperature drops, particularly in autumn and winter), positional exposure (when hands or feet emerge from bedding during normal sleep position changes — the seventeen to twenty position changes of normal sleep architecture repeatedly expose extremities to ambient air temperature), and the general nocturnal hypothermia of sleep (core body temperature normally drops approximately one to one-and-a-half degrees Celsius during sleep, with peripheral vasoconstriction that maintains core temperature at the cost of digital perfusion). For SSc patients with structurally compromised digital vasculature, the nocturnal peripheral vasoconstriction that is physiologically normal during sleep falls on arteries that cannot tolerate additional constriction without triggering vasospasm — making Raynaud's attacks at night not an unusual event but a highly predictable, nearly nightly occurrence in poorly controlled SSc. The pain of the Raynaud's reperfusion phase (the reactive hyperemia that follows vasospasm resolution) is the most acutely disruptive nocturnal event — the throbbing, burning pain of reperfusion awakens patients from sleep and typically requires several minutes of hand warming and active movement before settling. CBD addresses the neurogenic and autonomic components of SSc Raynaud's through two mechanisms: the ANS parasympathetic shift from CBD's adenosine/ENT1 blockade and CB1 endocannabinoid activation reduces sympathetic alpha-adrenergic tone on digital vasculature — the same mechanism that makes SSc Raynaud's attacks excessive is their alpha-adrenergic sympathetic overdrive, and CBD's parasympathetic-promoting ANS effect works in the physiologically correct direction (reducing sympathetic vasoconstriction drive); TRPV1 desensitization on the perivascular sensory nerve fibers that release vasoactive neuropeptides (substance P, CGRP) during vasospasm reduces the neurogenic component of the vasoconstriction (neurogenic inflammation around digital vessels contributes to sustained vasospasm, and TRPV1-desensitized perivascular sensory fibers release less substance P and CGRP during cold exposure, potentially reducing the vasoconstriction magnitude). Critically, the Raynaud's mechanism is the physiological inverse of erythromelalgia (heat-triggered vasodilation → burning redness, seen in PV and PsA): the behavioral adjunct for SSc Raynaud's sleep is warming the sleep environment (warm bedding, warm socks, heated mattress pad), in direct contrast to the cooling environment recommended for erythromelalgia sleep — the most mechanistically opposite behavioral recommendations in this series.
3. Fibrotic Chest Wall and ILD Respiratory Restriction Anxiety: Pre-Sleep Awareness of Reduced Respiratory Reserve in a Disease Where Breathing Has Become Mechanically Constrained
The respiratory component of SSc produces a sleep anxiety with no close analogue in this series. SSc patients with chest wall skin fibrosis and ILD face two distinct but reinforcing respiratory restrictions: external restriction from chest wall fibrosis (the tethering of skin to subcutaneous tissue and ribs by collagen deposition reduces chest wall expansion compliance, producing a restrictive defect in pulmonary function testing — reduced total lung capacity, forced vital capacity — from purely mechanical external compression by fibrotic skin) and internal restriction from ILD (fibrotic lung parenchyma with reduced alveolar compliance, impaired gas exchange, reduced diffusing capacity for carbon monoxide — DLCO). Either restriction alone would be manageable with adequate cardiopulmonary reserve; the combination produces an anxiety-inducing awareness that the respiratory system has both external mechanical limits and internal gas-exchange limits operating simultaneously. The pre-sleep period is when this respiratory awareness concentrates: when the SSc patient lies flat, diaphragmatic excursion is slightly reduced compared to sitting or standing (the standard 15–20% reduction in FVC in the supine position affects normal individuals minimally but is amplified in SSc by the fibrotic chest wall's reduced compliance in the supine position and the ILD's reduced lung compliance), and the patient may notice increased respiratory effort at rest in the supine position — a subtle but perceptible increase in work of breathing that is absent in the upright position during daytime activity. The awareness of increased respiratory effort at rest, in a condition where the disease trajectory is respiratory progression, populates the pre-sleep cognitive space with the most existentially acute anxiety in the SSc sleep profile: the recognition that breathing — effortful during daytime activity — becomes more effortful in the lying position before sleep, in a disease where ILD progression is the leading cause of mortality. Respiratory anxiety of this nature is distinct from the disease-progression anxieties in prior posts (spinal fusion anxiety in AS, lymphoma-vigilance in primary Sjögren's, TIA-vigilance in ET) in that it is somatically anchored — the patient is not imagining respiratory difficulty, they are perceiving genuine, objectively measurable increased work of breathing in the supine position, which gives the anxiety a reality-anchored quality that makes cognitive reframing difficult. CBD's 5-HT1A mechanism reduces the amygdala's threat-salience amplification of the perceived respiratory signal — not by suppressing respiratory awareness (appropriate for SSc disease monitoring) but by reducing the catastrophizing amplification loop that converts awareness of slightly increased breathing effort into a sustained pre-sleep panic episode. FAAH/HPA normalization addresses the chronic HPA dysregulation from longstanding disease burden and the anticipatory anxiety of lying down in a position that regularly triggers GERD and Raynaud's as well as respiratory discomfort — the SSc patient approaches sleep with a multi-channel threat-anticipation burden (will the acid reflux awaken me? will a Raynaud's attack wake me? will I feel short of breath?) that the HPA normalization mechanism directly addresses.
SSc Subtype and Organ Involvement: CBD Protocol Relevance
| SSc Profile | Primary Sleep Disruptors | CBD Mechanism Priority | Protocol Note |
|---|---|---|---|
| lcSSc (limited) with Raynaud's and esophageal dysmotility — CREST-pattern, skin limited to hands/face, primary vasculopathy and GI involvement | Nocturnal Raynaud's attacks from room temperature drops and positional hand exposure (primary SSc sleep disruptor in this subtype); nocturnal GERD and regurgitation in recumbency; Raynaud's reperfusion throbbing pain as acute awakening event; anticipatory anxiety about recumbency-triggered GERD | ANS parasympathetic shift (CB1 + adenosine/ENT1) for sympathetic alpha-adrenergic Raynaud's reduction — the primary mechanism targeting the Raynaud's vasospasm; CB1 enteric nervous system LES modulation for GERD; FAAH overnight ANS normalization; 5-HT1A for recumbency-anticipatory anxiety; Oil before bed + Softgels overnight GI coverage | Calcium channel blocker (nifedipine, amlodipine) CYP3A4 interaction most important for this profile. Warming behavioral adjuncts: warm socks, warm bedding, heated mattress pad — the sleep environment warming protocol that is the direct opposite of the erythromelalgia cooling protocol. Head-of-bed elevation (six to eight inches) for nocturnal GERD in addition to PPI as behavioral GI adjunct unique to SSc in this series. |
| dcSSc (diffuse) with ILD — rapid-onset skin thickening, ILD present, on MMF or cyclophosphamide | All three SSc sleep disruptors active: fibrotic chest wall respiratory restriction awareness in supine position; nocturnal GERD (esophageal dysmotility universal in SSc); Raynaud's; disease-trajectory anxiety (dcSSc carries higher ILD progression risk and more rapid disease course than lcSSc) | 5-HT1A and FAAH/HPA for the compounded respiratory-trajectory-existential anxiety burden; CB2/NF-κB and TGF-β pathway (CB2 reduces TGF-β-driven fibroblast activation — preclinical evidence for cannabinoid antifibrotic effect through CB2/PPARγ); ANS parasympathetic shift for Raynaud's; CB1/FAAH for LES; TRPV1 for reperfusion digit pain | MMF — UGT metabolism, clean CBD profile. Cyclophosphamide — CYP3A4 activation, theoretical interaction: disclose, time CBD away from IV infusion cycles. The dcSSc profile requires the most comprehensive multi-mechanism CBD protocol in the SSc group. Head-of-bed elevation and left lateral decubitus position for GI component. |
| SSc with PAH on PDE5 inhibitor or endothelin receptor antagonist — lcSSc-predominant, advanced pulmonary vascular disease | Exertional dyspnea awareness intensifying at rest in supine position; PAH-specific nocturnal hypoxemia anxiety; right heart failure symptom anxiety during pre-sleep period; Raynaud's; GERD | 5-HT1A for PAH-specific respiratory and right heart failure pre-sleep anxiety; FAAH/HPA for chronic cardiopulmonary disease burden; ANS parasympathetic shift for both Raynaud's and the sympathetic overdrive of compensated right heart failure; CB1/FAAH for GI motility | Most important CBD interaction in this profile: Sildenafil and tadalafil CYP3A4 — consult pulmonologist/cardiologist before CBD. Endothelin receptor antagonists (bosentan CYP3A4/2C9 inducer + substrate, ambrisentan CYP3A4) — complex interactions, consultation required. These patients are typically managed by specialist centers. CBD should be introduced only with specialist awareness and formal CYP interaction assessment. |
| SSc with severe GI dysmotility beyond esophagus — gastric dysmotility (gastroparesis), small bowel dysmotility, bacterial overgrowth (SIBO) | Nocturnal bloating, cramping, and bacterial overgrowth-related GI distress disrupting sleep; gastroparesis-related nausea and early satiety disrupting pre-sleep comfort; nocturnal diarrhea or incontinence from small bowel dysmotility; worsened supine GERD from delayed gastric emptying superimposing on esophageal dysmotility | CB1 enteric nervous system modulation throughout the GI tract — prokinetic-adjacent mechanism for GI smooth muscle dysmotility (CB1 reduces enteric inhibitory tone, promoting motility); TRPV1 desensitization in the GI epithelium for visceral pain and cramping; FAAH for enteric neuroinflammation; 5-HT1A for GI-anxiety component | The most complex SSc GI profile. PPIs (omeprazole, pantoprazole) CYP2C19 interaction — modest. Prokinetics (metoclopramide — D2 antagonist, CYP2D6; domperidone — CYP3A4 most important, CYP2D6 secondary): CBD modest CYP2D6 inhibition with metoclopramide; CYP3A4 interaction with domperidone (not available in US, used internationally) — relevant for international SSc patients. Prucalopride (5-HT4 agonist for small bowel dysmotility) — primarily CYP3A4 substrate, modest CBD interaction. |
Population Profiles
lcSSc Raynaud's-and-GERD Dominant Protocol: Warming Behavioral Adjuncts, ANS Parasympathetic CBD Oil for Vasospasm Reduction and LES Modulation, and Head-of-Bed Elevation for the Most Distinctly SSc Sleep Pattern in the Series
For the limited SSc patient whose primary sleep disruptors are nocturnal Raynaud's attacks and recumbency-triggered GERD, the protocol is built around the ANS parasympathetic shift and CB1/FAAH enteric mechanisms with warming environmental adjuncts. The Nano CBD Broad Spectrum Oil taken sixty minutes before bed provides the systemic ANS parasympathetic shift (adenosine/ENT1 + CB1 endocannabinoid) that reduces sympathetic alpha-adrenergic digital vasoconstriction tone — the direct mechanism against Raynaud's nocturnal vasospasm — and the CB1/FAAH enteric nervous system modulation of the LES and esophageal neurogenic dysfunction contributing to GERD. The Nano CBD Water-Soluble Broad Spectrum Softgels maintain overnight FAAH elevation and CB1 enteric coverage across the full nocturnal GERD window. The Nano CBD Muscle and Joint Cream applied to hands and fingers before bed addresses the Raynaud's at the tissue level — TRPV1 desensitization on perivascular sensory fibers reduces neurogenic inflammation-driven vasoconstriction magnitude, and CB2/NF-κB reduces the ongoing vascular neuroinflammation of SSc vasculopathy. Importantly, applying Cream to hands before bed is also a warming action — physical manipulation and application increases local hand temperature, which is the most direct Raynaud's prevention behavioral adjunct. The CBD+CBN+D9+Melatonin Gummies address sleep-onset anxiety about recumbency triggers (melatonin for sleep-onset, CBN for return-to-sleep after Raynaud's-awakening or GERD-awakening, D9 for slow-wave sleep restoration in chronically disrupted SSc architecture). The Nano CBD Full Spectrum Berry Gummies provide 5-HT1A for recumbency-anticipatory anxiety. The Nano CBD Broad Spectrum Gummies maintain daytime CB2 and ANS balance. The Nano CBD Elderberry Gummies provide quercetin's vascular antioxidant support and NF-κB inhibitory complement to the SSc vasculopathy inflammatory substrate.
dcSSc With ILD Respiratory Anxiety Protocol: 5-HT1A-Led Fibrotic Chest Wall and Lung Progression Anxiety, CB2/TGF-β Complementary Antifibrotic Support, and the Comprehensive Multi-Channel Disruption Protocol
For the diffuse SSc patient with ILD and the full tri-channel sleep disruption (GERD + Raynaud's + respiratory restriction anxiety), the protocol leads with 5-HT1A and FAAH/HPA for the compounded existential burden of a rapidly progressive fibrotic disease while maintaining all three mechanistic layers. The Nano CBD Full Spectrum Berry Gummies lead for this profile — the terpene-enhanced 5-HT1A for the respiratory-trajectory existential anxiety that is the defining psychological burden of dcSSc. The Nano CBD Broad Spectrum Oil delivers the systemic ANS, CB1 GI, CB2/NF-κB antifibrotic, and FAAH/HPA mechanisms simultaneously — the Oil is the multi-mechanism systemic layer for a disease where multiple organ systems are simultaneously disrupted. CB2/PPARγ activation's preclinical antifibrotic signal (CB2 receptors on fibroblasts, when activated, reduce TGF-β-driven myofibroblast differentiation and collagen synthesis in preclinical models of fibrosis) makes the CB2 mechanism uniquely interesting in SSc beyond its anti-inflammatory role in the synovial conditions of prior posts. The Nano CBD Muscle and Joint Cream applied to hands for Raynaud's digit TRPV1 desensitization and perivascular neuroinflammation. The CBD+CBN+D9+Melatonin Gummies for sleep architecture restoration in the multi-awakening SSc pattern. The Nano CBD Water-Soluble Broad Spectrum Softgels for overnight CB1 GI and FAAH coverage. The Nano CBD Elderberry Gummies for the vascular and antifibrotic antioxidant complement.
CBD Oil Protocol for SSc Sleep Disruption
The SSc Protocol: Rheumatologist and Pulmonologist Disclosure With Calcium Channel Blocker and PDE5 Inhibitor CYP3A4 Priority, Head-of-Bed Elevation and Warming Environment as SSc-Specific Behavioral Adjuncts Unique in This Series, and PSQI Plus Raynaud's Attack Frequency Plus Nocturnal GERD Episode Tracking
Specialist disclosure hierarchy — calcium channel blocker and PDE5 inhibitor CYP3A4 as most important interactions, MMF as clean profile, cyclophosphamide timing consideration: SSc is typically managed by a specialist team — rheumatologist (skin and systemic disease), pulmonologist (ILD), cardiologist or PAH specialist (PAH), and gastroenterologist (GI dysmotility). CBD disclosure should reach the prescribing rheumatologist as the coordinating physician. Priority interactions: calcium channel blocker (nifedipine, amlodipine, diltiazem — CYP3A4, moderate interaction) for Raynaud's management — most commonly encountered in lcSSc; PDE5 inhibitor (sildenafil, tadalafil — CYP3A4) and endothelin receptor antagonists for PAH — most consequential CYP interaction given the hemodynamic stakes of PAH medication levels; nintedanib (CYP3A4) or pirfenidone (CYP1A2/minor CYPs) for ILD — requires pulmonologist consultation. MMF — clean profile, no dose adjustment. Cyclophosphamide — time CBD away from IV infusion cycles.
SSc-specific behavioral adjuncts unique in this series: Two behavioral adjuncts for SSc sleep are unique in this series and have no equivalent in any prior post. (1) Head-of-bed elevation (six to eight inches using bed risers or a wedge pillow, not pillow stacking which inadequately elevates the entire torso) — elevating the upper body relative to the stomach reduces the hydrostatic pressure driving nocturnal acid reflux through the incompetent LES and reduces the esophageal pooling time of refluxed acid; this is standard GERD sleep advice but has particular urgency in SSc where acid microaspiration contributes to ILD progression. (2) Sleep environment warming — warm socks, heated mattress pad or electric blanket on low, and maintaining bedroom temperature above eighteen to twenty degrees Celsius — directly addresses the nocturnal temperature-drop Raynaud's trigger. The warming protocol for SSc is the direct behavioral inverse of the cooling protocol for erythromelalgia (erythromelalgia patients keep bedrooms cool and use minimal covering); the two protocols are mutually exclusive and reflect the opposite vascular physiology of cold-triggered vasoconstriction (Raynaud's) versus heat-triggered vasodilation (erythromelalgia). Left lateral decubitus sleep position (lying on the left side) is recommended for SSc GERD — it reduces the exposure of the LES to the gastric pool and limits reflux opportunity — as a positional GI adjunct.
Tracking: Raynaud's attack frequency + GERD episode count + PSQI + respiratory comfort VAS: SSc sleep tracking requires monitoring across all three disruption channels simultaneously. Raynaud's attack frequency: number of nocturnal attacks per week (defined as any awakening associated with digit color change and pain); Raynaud's attack severity VAS (0–10, intensity of reperfusion pain). GERD episode frequency: number of nocturnal acid-awakening or coughing/choking events per week (tracked in a sleep log). Respiratory comfort: nightly 0–10 VAS of supine respiratory comfort at bedtime (tracks the pre-sleep respiratory anxiety component). PSQI at four and eight weeks captures the integrated sleep quality improvement. The three-channel tracking gives patients and clinicians the ability to distinguish which mechanism is responding first — the Raynaud's and GERD channels typically provide earlier response signals (ANS and TRPV1 mechanisms, weeks two to four) while the respiratory anxiety channel responds more slowly as 5-HT1A accumulates (weeks four to eight).
PureCraft Products for SSc Sleep Disruption
ANS Parasympathetic Shift for Raynaud's Vasospasm, CB1/FAAH Enteric Nervous System for Esophageal Dysmotility, CB2/TGF-β for Fibrotic Inflammatory Substrate, 5-HT1A for Respiratory Restriction Anxiety: The SSc Mechanism Stack
The Nano CBD Broad Spectrum Oil taken sixty minutes before sleep provides the complete SSc mechanism stack — ANS parasympathetic shift for sympathetic alpha-adrenergic Raynaud's reduction, CB1/FAAH enteric nervous system modulation of the LES and esophageal neurogenic dysfunction, CB2/NF-κB/PPARγ for the TGF-β fibrotic inflammatory environment, 5-HT1A for respiratory restriction and disease-trajectory anxiety, and FAAH/HPA for the multi-channel allostatic burden of a multi-organ progressive fibrotic disease. The Nano CBD Muscle and Joint Cream applied to hands before bed delivers TRPV1 desensitization to perivascular sensory fibers of the digit vasculature and CB2 to the SSc vasculopathic vascular neuroinflammation, while the physical act of Cream application warms the hands — the most direct Raynaud's prevention behavioral adjunct combined with the TRPV1 topical mechanism in a single pre-sleep action. The Nano CBD Water-Soluble Broad Spectrum Softgels sustain FAAH elevation and CB1 GI coverage overnight. The CBD+CBN+D9+Melatonin Gummies provide melatonin for sleep-onset, CBN for return-to-sleep after Raynaud's or GERD awakenings, and D9 for slow-wave architecture restoration in chronically disrupted SSc sleep. The Nano CBD Full Spectrum Berry Gummies deliver terpene-enhanced 5-HT1A for the respiratory-trajectory existential burden. The Nano CBD Broad Spectrum Gummies maintain daytime CB2 and ANS parasympathetic baseline. The Nano CBD Elderberry Gummies provide quercetin's vascular antioxidant and anti-inflammatory support for the SSc vasculopathic and fibrotic substrate — quercetin's anti-fibrotic preclinical signal (NF-κB and TGF-β pathway inhibition by quercetin has been shown in pulmonary fibrosis and vascular fibrosis models) makes it a particularly relevant nutraceutical complement in SSc.
Frequently Asked Questions About CBD Oil for Systemic Sclerosis Sleep
Does CBD oil help with Raynaud's phenomenon at night in scleroderma?
Raynaud's phenomenon in SSc has both a functional (vasospastic) component and a structural (vasculopathic — capillary loss, luminal narrowing) component. CBD addresses the functional vasospastic component through two mechanisms that operate in the physiologically correct direction. First, the ANS parasympathetic shift: CBD's ability to enhance parasympathetic tone (through adenosine transporter inhibition elevating adenosine at A1/A2A receptors, and through CB1 endocannabinoid activation reducing sympathetic drive) directly opposes the excessive sympathetic alpha-2 adrenergic vasoconstriction that triggers Raynaud's vasospasm. The sympathetic nervous system is the primary driver of Raynaud's vasospasm — cold-triggered sympathetic activation of alpha-2 adrenergic receptors on digital artery smooth muscle produces the vasoconstriction; CBD's parasympathetic-enhancing effect reduces baseline sympathetic tone and thus lowers the vasospastic trigger threshold. This mechanism does not reverse the structural capillary loss or arterial intimal narrowing of SSc vasculopathy, but it addresses the neurogenic vasospastic component that amplifies the structural limitation. Second, TRPV1 desensitization on perivascular sensory nerve fibers: sensory C-fibers expressing TRPV1 surround digital vessels and release vasoactive neuropeptides (substance P, CGRP) during cold activation, contributing to neurogenic inflammation around the vessel that sustains vasoconstriction. TRPV1 desensitization reduces this neurogenic vascular inflammatory contribution to the sustained vasospasm phase. Topical Cream to the hands before bed provides the most direct tissue-level mechanism delivery to the digital vessels. Clinically, the expectation should be modest-to-moderate reduction in nocturnal Raynaud's attack frequency and severity — not elimination of attacks, since the structural SSc vasculopathy component cannot be pharmacologically reversed — with the greatest response signal in Raynaud's that is neurogenically or autonomically amplified (which most SSc Raynaud's is, on top of the structural substrate). Warming behavioral adjuncts (warm socks, heated mattress pad) work synergistically with CBD's ANS mechanism by reducing the cold temperature trigger magnitude while CBD reduces the vasospastic response magnitude to remaining cold exposures.
Does CBD oil help with the acid reflux and GERD that wakes me up at night with scleroderma?
Nocturnal GERD in SSc is mechanistically distinct from the GERD of peptic ulcer disease, hiatal hernia, or dietary-trigger GERD — the SSc GERD is driven by the structural and neurogenic failure of the esophageal smooth muscle and lower esophageal sphincter from fibrosis and autonomic neuropathy, not by excessive acid production (which is why PPIs reduce symptom severity but do not address the underlying dysmotility). CBD's CB1 mechanism in the enteric nervous system provides a relevant biological rationale for the neurogenic component of SSc esophageal dysfunction. CB1 receptors are present throughout the enteric nervous system — on inhibitory motor neurons in the LES, on esophageal sensory neurons, and on the interstitial cells of Cajal that regulate GI smooth muscle contractility. In SSc, the early autonomic neuropathic phase of esophageal involvement produces neurogenic LES and peristaltic dysfunction before fibrosis is established; even in established fibrotic SSc esophageal disease, residual neurogenic dysfunction coexists with the structural fibrotic component. CBD's FAAH inhibition elevates anandamide at these enteric CB1 receptors, modulating the inhibitory tone on LES neuromotor function and potentially supporting LES competence and residual peristaltic function through the neurogenic/cholinergic component. Additionally, CBD's 5-HT1A mechanism at the level of the dorsal nucleus of the vagus nerve — where vagal efferents to the esophagus originate — may support vagal cholinergic tone to the esophageal smooth muscle: the vagus nerve (parasympathetic) drives esophageal peristalsis and LES tone, and 5-HT1A at the dorsal vagal nucleus modulates vagal efferent activity. Whether this translates to clinically meaningful LES pressure improvement in established SSc is not established by clinical trial data, but the mechanistic rationale is genuinely distinct from the zero-mechanism rationale CBD would have for GERD driven purely by acid overproduction (where CBD has no relevant mechanism). CBD does not replace PPIs or prokinetics for SSc GERD; head-of-bed elevation and left lateral decubitus positioning provide the most reliable behavioral GERD reduction. CBD's CB1/FAAH neurogenic mechanism is a complementary biological layer in a condition where the GERD has a significant neurogenic component alongside the structural fibrotic one.
Does CBD oil help with breathing anxiety and respiratory discomfort that makes it hard to fall asleep with scleroderma?
The respiratory restriction anxiety of SSc is among the most challenging sleep anxieties in this series to address because, unlike the abstract disease-progression anxieties of AS (spinal fusion fear) or ET (lymphoma transformation), the SSc respiratory anxiety is somatically grounded — the patient is perceiving genuine, physiologically real increased work of breathing in the supine position from fibrotic chest wall compliance reduction and ILD-impaired lung compliance. This somatic reality-grounding of the anxiety makes pure cognitive reframing difficult (the perception is accurate — breathing is objectively slightly more effortful supine than upright in SSc) and makes the anxiety qualitatively distinct from phobic or catastrophizing anxiety states. CBD's 5-HT1A mechanism at the prefrontal cortex-amygdala circuit addresses the key neurobiological problem: the amygdala's threat-salience amplification of the respiratory signal. In SSc, the perception of slightly increased respiratory effort is real; the catastrophizing amplification that converts "breathing feels slightly more work" into a sustained pre-sleep panic episode — populating the pre-sleep cognitive space with respiratory anxiety thoughts and driving anticipatory anxiety about lying down — is the component that 5-HT1A addresses. 5-HT1A partial agonism at the prefrontal cortex reduces the amygdala's threat-salience weight assigned to the respiratory signal: the patient can remain aware of their breathing (appropriate disease monitoring) without the awareness triggering a catastrophizing chain. FAAH/HPA normalization addresses the secondary layer — the chronic anticipatory anxiety about recumbency that builds over repeated nights of GERD and Raynaud's awakenings (the SSc patient approaches sleep with a multi-threat expectation that further amplifies respiratory anxiety). CBD does not improve respiratory mechanics, lung compliance, or FVC in SSc — no cannabinoid has demonstrated spirometric improvement in ILD. The target is specifically the anxiety amplification circuit that converts real respiratory awareness into pre-sleep panic, not the underlying pulmonary restriction. Practical note for respiratory management: pulse oximetry at night (available commercially) can provide objective reassurance that oxygen saturation is maintained during sleep for patients who are concerned about nocturnal hypoxemia — turning an anxiety about an unknown quantity into a monitored data point sometimes reduces the anticipatory anxiety more than pharmacological intervention alone.
How is Raynaud's phenomenon in scleroderma different from erythromelalgia, and why does that matter for CBD oil use and sleep?
Raynaud's phenomenon and erythromelalgia are the two primary vascular extremity pain conditions affecting sleep in this series, and they are physiological opposites in every relevant dimension — understanding the distinction is essential for correct CBD sleep protocol design. Raynaud's (SSc, primary Raynaud's, other secondary causes): triggered by cold and emotional stress; mechanism is excessive sympathetic alpha-adrenergic vasoconstriction producing digital ischemia; clinical sequence is pallor (ischemia) → cyanosis (deoxygenation) → reactive erythema (reperfusion); pain is primarily from the reactive hyperemia reperfusion phase (throbbing, burning from sudden blood return to ischemic tissue); the digit is cold, pale, then blue, then red. Erythromelalgia (PV in P11-267, PsA-adjacent in P11-270, ET in P11-268): triggered by heat and exercise; mechanism is platelet-mediated microvascular thrombosis (in MPN) or vasodilatation failure; clinical sequence is erythema (vasodilation or thrombosis) → burning — there is no pallor or cyanosis phase; pain is from the heat-triggered vasodilation or microvascular occlusion, not reperfusion; the digit is hot and red, not cold. This distinction inverts the behavioral sleep protocol: SSc Raynaud's requires warming the sleep environment — warm socks, warm bedding, high room temperature — to prevent cold-trigger vasospasm; erythromelalgia requires cooling the sleep environment — cool room, minimal bedding, ice water proximity — to prevent heat-trigger vasodilation and burning. For CBD's ANS mechanism: the sympathetic-reducing, parasympathetic-promoting ANS shift of CBD directly benefits Raynaud's (whose mechanism is sympathetic vasoconstriction excess) but would be neutral-to-slightly-beneficial in erythromelalgia (where vasodilation rather than vasoconstriction is the primary mechanism). For TRPV1: both Raynaud's and erythromelalgia have sensitized peripheral TRPV1 contributing to their respective pain phases, but the temperature stimulus profiles are opposite — cold in Raynaud's (where TRPV1 cold-activation through the TRPA1 channel cross-sensitization is relevant), heat in erythromelalgia (where thermal TRPV1 activation is the primary pruritoceptive/nociceptive mechanism). TRPV1 desensitization benefits both conditions but through different ends of its temperature-sensing range. If a patient has both Raynaud's and erythromelalgia (which can co-exist in some conditions, including SSc where erythromelalgia-like reperfusion can occur), the behavioral protocol requires nuanced temperature management — a situation worth discussing with the treating rheumatologist.
Does CBD oil interact with nifedipine or amlodipine for Raynaud's in scleroderma?
Calcium channel blockers (CCBs) are the first-line pharmacological treatment for SSc Raynaud's — nifedipine (dihydropyridine, extended-release form preferred) and amlodipine (dihydropyridine, longer half-life) are the most commonly used, with diltiazem (non-dihydropyridine) as an alternative. All three are CYP3A4 substrates, and CBD is a moderate CYP3A4 inhibitor — this combination warrants rheumatologist disclosure and monitoring. The pharmacokinetic mechanism: CBD's inhibition of CYP3A4 in the small intestinal enterocytes and hepatocytes (the primary sites of first-pass and systemic CYP3A4 metabolism of CCBs) can reduce the CYP3A4-mediated clearance of the CCB, increasing peak plasma levels and prolonging exposure. For nifedipine, which already produces dose-related side effects of flushing, headache, dizziness, and ankle edema — particularly in extended-release form where sustained blood levels are already maintained — a modest CYP3A4-mediated increase in nifedipine exposure could amplify these side effects. For amlodipine, with its very long half-life (thirty to fifty hours), the accumulation of elevated plasma levels from reduced CYP3A4 clearance could produce more sustained hypotension and edema. Practical guidance: disclose CBD to the rheumatologist who prescribes the CCB for Raynaud's; start CBD at a low dose (fifteen to twenty-five mg) and observe for enhanced CCB side effects (increased flushing, headache, ankle edema, or lightheadedness upon standing); if tolerated without amplified CCB side effects for two weeks, gradually increase CBD dose. The interaction is moderate rather than severe — it does not preclude combining CBD with CCBs, but it requires the same monitored introduction approach as any CYP3A4 combination. The therapeutic goal (CBD reducing sympathetic Raynaud's vasospasm via ANS mechanism + CCB blocking L-type calcium channels in smooth muscle for vasodilation) is mechanistically complementary — both reduce digital vasoconstriction through different mechanisms — making the combination potentially beneficial if the CYP interaction is managed through appropriate dose titration.
How does CBD oil for scleroderma sleep differ from CBD oil for Sjögren's syndrome or ankylosing spondylitis sleep?
SSc, primary Sjögren's syndrome, and AS represent three distinct autoimmune connective tissue conditions in this series, each with genuinely different sleep disruption profiles. Versus AS (P11-269): AS produces axial inflammatory back pain with the pathognomonic two-to-five AM forced-rising awakening from the cortisol-nadir cytokine surge — the sleep disruption is entirely pain-and-immobility based, with no GI, vascular, or skin component. SSc sleep disruption is GI (GERD), vascular (Raynaud's), and respiratory (ILD/chest wall restriction) — none of which are present in AS. AS uses Cream on the lumbar/sacral region; SSc uses Cream on the hands. AS Oil timing is sixty to ninety minutes for cytokine surge coverage; SSc Oil timing is sixty minutes for Raynaud's vasospastic prophylaxis and LES neurogenic support. AS behavioral adjunct is sleeping position optimization for sacroiliac pain; SSc behavioral adjuncts are head-of-bed elevation (GERD), left lateral decubitus (GERD), and environmental warming (Raynaud's) — each unique to SSc in the series. Versus primary Sjögren's syndrome: both share the systemic autoimmune basis and the 5-HT1A anxiety mechanism (Sjögren's lymphoma-vigilance anxiety; SSc respiratory-trajectory anxiety), but their primary sleep disruptors are completely different — Sjögren's is dominated by xerostomia dry-mouth awakenings requiring water drinking (CB1 submandibular gland mechanism), small fiber neuropathy burning pain, and fatigue-hypersomnolence conflict; SSc has none of these and instead has GERD, Raynaud's, and respiratory restriction. The GI mechanism in SSc is CB1 enteric LES modulation; in Sjögren's the CB1 mechanism targets salivary gland secretion — different organs, different functional endpoints, same receptor family. Mechanistically, SSc is the most ANS-mechanism-dependent post in the series (Raynaud's vasospasm reduction is the primary ANS-targeted sleep disruption), while Sjögren's is the most CB1-secretory-mechanism-dependent (xerostomia). SSc is the only condition in this series where a warming sleep environment is a prescribed behavioral adjunct; Sjögren's (small fiber neuropathy) shares some thermal sensory features with erythromelalgia conditions but does not require warming or cooling protocol specifically.
Related Articles
- → CBD Oil for Sleep and Psoriatic Arthritis: Dual Dermal-Articular Sleep Disruption, Dactylitis Positional Pain, and the IL-17A/CB2/TRPV1 Protocol
- → CBD Oil for Sleep and Ankylosing Spondylitis: Inflammatory Nocturnal Back Pain, Morning Stiffness, and the HLA-B27 CB2/NF-κB Sleep Protocol
- → CBD Oil for Sleep and Polycythemia Vera: Aquagenic Pruritus, Erythromelalgia, and the JAK2 V617F MPN Sleep Protocol
- → CBD Oil for Sleep and Ehlers-Danlos Syndrome: Hypermobility Joint Instability, Nocturnal Subluxation Pain, and the Connective Tissue Sleep Protocol
- → CBD Oil for Sleep and Interstitial Cystitis: Bladder Pain Nocturia, TRPV1 Urothelial Sensitization, and the IC/BPS Sleep Protocol
References
- Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
- Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
- Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
- Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
- Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352
Medical Disclaimer
This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including systemic sclerosis, scleroderma, Raynaud's phenomenon, interstitial lung disease, or pulmonary arterial hypertension. CBD oil is not a substitute for rheumatologist-, pulmonologist-, or cardiologist-directed SSc management, immunosuppressive therapy, vasodilator treatment, or antifibrotic therapy. Patients on calcium channel blockers (nifedipine, amlodipine, diltiazem) or PDE5 inhibitors (sildenafil, tadalafil) must disclose CBD use to their prescribing physician due to CYP3A4 interactions. Patients on nintedanib, endothelin receptor antagonists, or cyclophosphamide should consult their specialist before adding CBD. CBD does not treat systemic sclerosis, reverse fibrosis, improve lung function, or replace prescribed disease-modifying therapy. Patients with pulmonary arterial hypertension should not add any supplement to their PAH medication regimen without specialist consultation. The statements in this article have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual responses to CBD vary significantly.
